Thiogenesis Therapeutics, Corp.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

thiogenesis.com

Country

Canada

Exchange

TSXV

Toronto, Canada

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.

Key Stats

52-Week Range

C$0.44C$0.87

Beta0.57

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.14

Avg Volume

Earnings & Analyst

Next Earnings2026-08-25

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.